Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Dapagliflozin is associated with greater reductions in HbA1c and weight than saxagliptin in management of type 2 diabetes mellitus (T2DM). The present post hoc analyses compared the durability of these effects over short‐ and long‐term follow‐up in patients with T2DM who were inadequately controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Clifford J., Del Prato, Stefano, Wei, Cheryl, Reyner, Daniel, Saraiva, Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851837/
https://www.ncbi.nlm.nih.gov/pubmed/31364269
http://dx.doi.org/10.1111/dom.13841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851837/
https://www.ncbi.nlm.nih.gov/pubmed/31364269
http://dx.doi.org/10.1111/dom.13841

Ejemplares similares